Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir douche for HIV prevention in adolescent men
NCT04686279Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tenofovir in human immunodeficiency virus infection (HIV), sponsored by University of Pennsylvania. Primary endpoints: Tenofovir Diphosphate Concentration at 72 hours and Acceptability of TFV Douche at 1 hour. Started Apr 2021; status: completed.
02
Drugs
tenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04686279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686279.